Comparing Efficacy and Safety of Various Monoclonal Antibodies in Myasthenia Gravis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials - PubMed
3 hours ago
- #myasthenia gravis
- #network meta-analysis
- #monoclonal antibodies
- This study is a systematic review and network meta-analysis comparing monoclonal antibodies for myasthenia gravis treatment.
- Rozanolixzumab (ROZ) 10 mg/kg was ranked best for improving MG-ADL scores, showing significant reduction versus placebo.
- Batoclimab (BAT) 680 mg was top-ranked for reducing QMG scores, with a significant decrease compared to placebo.
- Eculizumab (ECU) ranked best for enhancing MG-QoL 15r scores, and Belimumab (BEL) 10 mg/kg was best for reducing adverse events.
- The analysis included 18 RCTs, using p-scores for treatment rankings, highlighting differences in efficacy across various outcome measures.